UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 73

Sortiert nach

ACoP: The Tools, Carpenters, and Architects Building the Discipline of Pharmacometrics

Journal of clinical pharmacology, 2010-09, Vol.50 (S9), p.7S-8S

2010

Volltextzugriff (PDF)

Affiliation between the American Society of Pharmacometrics and the Journal of Pharmacokinetics and Pharmacodynamics

Journal of pharmacokinetics and pharmacodynamics, 2012-02, Vol.39 (1), p.3-3

2012

Volltextzugriff (PDF)

Bayesian modeling and simulation to inform rare disease drug development early decision-making: Application to Duchenne muscular dystrophy

PloS one, 2022-04, Vol.17 (4), p.e0247286-e0247286

2022

Volltextzugriff (PDF)

Big Data: Challenges and opportunities for clinical pharmacology

British journal of clinical pharmacology, 2016-05, Vol.81 (5), p.804-806

2016

Volltextzugriff (PDF)

Brief Report: CYP2B6 516G>T Minor Allele Protective of Late Virologic Failure in Efavirenz-Treated HIV-Infected Patients in Botswana

Journal of acquired immune deficiency syndromes (1999), 2017-08, Vol.75 (4), p.488

2017

Volltextzugriff (PDF)

Challenging the Norm: A Multidisciplinary Perspective on Intravenous to Subcutaneous Bridging Strategies for Biologics

Clinical pharmacology and therapeutics, 2024-03, Vol.115 (3), p.412-421

2024

Volltextzugriff (PDF)

Combining patient-level and summary-level data for Alzheimer’s disease modeling and simulation: a beta regression meta-analysis

Journal of pharmacokinetics and pharmacodynamics, 2012-10, Vol.39 (5), p.479-498

2012

Volltextzugriff (PDF)

Corrigendum: 2016 ACG Abstracts-Inflammatory Bowel Disease

The American journal of gastroenterology, 2017-07, Vol.112 (7), p.1209-1210

2017

Volltextzugriff (PDF)

Defining the Future of Pharmacometrics: The American Society of Pharmacometrics

Journal of clinical pharmacology, 2010-09, Vol.50 (S9), p.158S-158S

2010

Volltextzugriff (PDF)

Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy

The AAPS journal, 2006-09, Vol.8 (3), p.E552-E563

2006

Volltextzugriff (PDF)

Dexmedetomidine Pharmacology in Neonates and Infants After Open Heart Surgery

Anesthesia and analgesia, 2016-05, Vol.122 (5), p.1556-1566

2016

Volltextzugriff (PDF)

Distinction between the in vitro and in vivo inhibitory effects of morphine on lymphocyte proliferation based on agonist sensitivity and naltrexone reversibility

Immunopharmacology, 1992-03, Vol.23 (2), p.117-124

1992

Volltextzugriff (PDF)

The Effect of Reporting Methods for Dosing Times on the Estimation of Pharmacokinetic Parameters of Escitalopram

Journal of clinical pharmacology, 2009-02, Vol.49 (2), p.176-184

2009

Volltextzugriff (PDF)

Evaluating the Consistency of Pharmacotherapy Exposure by Use of State-of-the-Art Techniques

The American journal of geriatric psychiatry, 2002-11, Vol.10 (6), p.696-705

2002

Volltextzugriff (PDF)

Exposure-response modeling and clinical trial simulation of the effect of tolterodine on QT intervals in healthy volunteers

Drug discoveries & therapeutics, 2010-02, Vol.4 (1), p.44-53

2010

Volltextzugriff (PDF)

Exposure−response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes

British journal of clinical pharmacology, 2014-12, Vol.78 (6), p.1407-1418

2014

Volltextzugriff (PDF)

Facilitating pharmacometric workflow with the metrumrg package for R

Computer methods and programs in biomedicine, 2013-01, Vol.109 (1), p.77-85

2013

Volltextzugriff (PDF)

Fluconazole Dosing for the Prevention or Treatment of Invasive Candidiasis in Young Infants

The Pediatric infectious disease journal, 2009-08, Vol.28 (8), p.717-723

2009

Volltextzugriff (PDF)

Impaired 6-hydroxychlorzoxazone elimination in patients with kidney disease: Implication for cytochrome P450 2E1 pharmacogenetic studies

Clinical pharmacology and therapeutics, 2003-12, Vol.74 (6), p.555-568

2003

Volltextzugriff (PDF)

Latent process model of the 6-minute walk test in Duchenne muscular dystrophy

Journal of pharmacokinetics and pharmacodynamics, 2020-02, Vol.47 (1), p.91-104

2020

Volltextzugriff (PDF)

Latent process model of the 6-minute walk test in Duchenne muscular dystrophy: A Bayesian approach to quantifying rare disease progression

Journal of pharmacokinetics and pharmacodynamics, 2020-02, Vol.47 (1), p.91-104

2020

Volltextzugriff (PDF)

MID3: Mission Impossible or Model‐Informed Drug Discovery and Development? Point‐Counterpoint Discussions on Key Challenges

Clinical pharmacology and therapeutics, 2020-04, Vol.107 (4), p.762-772

2020

Volltextzugriff (PDF)

Midazolam Dose Optimization in Critically Ill Pediatric Patients With Acute Respiratory Failure: A Population Pharmacokinetic-Pharmacogenomic Study

Critical care medicine, 2019-04, Vol.47 (4), p.e301

2019

Volltextzugriff (PDF)

Missing Data in Model-Based Pharmacometric Applications: Points to Consider

Journal of clinical pharmacology, 2010-09, Vol.50 (S9), p.63S-74S

2010

Volltextzugriff (PDF)

Mo1225 Population Pharmacokinetic Modeling of Vedolizumab in Patients With Ulcerative Colitis or Crohn's Disease

Gastroenterology (New York, N.Y. 1943), 2014-05, Vol.146 (5), p.S-591-S-591

2014

Volltextzugriff (PDF)

1 – 25 von 73

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(73)
Mit Volltextzugriff
(48)

Publikationsform

Artikel
(73)

Sprache

Englisch
(73)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

ACoP: The Tools, Carpenters, and Architects Building the Discipline of Pharmacometrics

Affiliation between the American Society of Pharmacometrics and the Journal of Pharmacokinetics and Pharmacodynamics

Bayesian modeling and simulation to inform rare disease drug development early decision-making: Application to Duchenne muscular dystrophy

Big Data: Challenges and opportunities for clinical pharmacology

Brief Report: CYP2B6 516G>T Minor Allele Protective of Late Virologic Failure in Efavirenz-Treated HIV-Infected Patients in Botswana

Challenging the Norm: A Multidisciplinary Perspective on Intravenous to Subcutaneous Bridging Strategies for Biologics

Combining patient-level and summary-level data for Alzheimer’s disease modeling and simulation: a beta regression meta-analysis

Corrigendum: 2016 ACG Abstracts-Inflammatory Bowel Disease

Defining the Future of Pharmacometrics: The American Society of Pharmacometrics

Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy

Dexmedetomidine Pharmacology in Neonates and Infants After Open Heart Surgery

Distinction between the in vitro and in vivo inhibitory effects of morphine on lymphocyte proliferation based on agonist sensitivity and naltrexone reversibility

The Effect of Reporting Methods for Dosing Times on the Estimation of Pharmacokinetic Parameters of Escitalopram

Evaluating the Consistency of Pharmacotherapy Exposure by Use of State-of-the-Art Techniques

Exposure-response modeling and clinical trial simulation of the effect of tolterodine on QT intervals in healthy volunteers

Exposure−response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes

Facilitating pharmacometric workflow with the metrumrg package for R

Fluconazole Dosing for the Prevention or Treatment of Invasive Candidiasis in Young Infants

Impaired 6-hydroxychlorzoxazone elimination in patients with kidney disease: Implication for cytochrome P450 2E1 pharmacogenetic studies

Latent process model of the 6-minute walk test in Duchenne muscular dystrophy

Latent process model of the 6-minute walk test in Duchenne muscular dystrophy: A Bayesian approach to quantifying rare disease progression

MID3: Mission Impossible or Model‐Informed Drug Discovery and Development? Point‐Counterpoint Discussions on Key Challenges

Midazolam Dose Optimization in Critically Ill Pediatric Patients With Acute Respiratory Failure: A Population Pharmacokinetic-Pharmacogenomic Study

Missing Data in Model-Based Pharmacometric Applications: Points to Consider

Mo1225 Population Pharmacokinetic Modeling of Vedolizumab in Patients With Ulcerative Colitis or Crohn's Disease

Suchergebnisse filtern